The Motley Fool Australia13m agoAt $199, are CSL shares a bargain buy or a risky investment?CSL Ltd (ASX: CSL) shares have rebounded 116% from a 10-year low recorded in June. Can they keep climbing higher?13m ago
Times Now1h agoNvidia Rules Out Jensen Huang Return as Revenue Surges and AI Chip Sales Set RecordRevenue at the company's data centre business rose 110% to $107.6bn. Nvidia expects revenue of $13bn in the current quarter. The guidance came in above analysts' expectations.1h ago
BeInCrypto1h agoSpaceX Stock Adds $54 Billion as AI-in-Space Discussion Goes ViralSpaceX added about $54 billion in market value on Tuesday. Its shares rose nearly 3%. Chief Financial Officer Bret Johnsen said the company could become one of the world's largest AI infrastructure providers as early as 2027.1h ago
Seeking Alpha1h agoInterGroup reports first-quarter resultsInterGroup's net loss widened to $2.24 million. EBITDA fell 33.8% year over year.1h ago
The Motley Fool Australia1h agoCatapult Sports shares fall 17%Catapult Sports' net loss widened to US$19.1 million. Annualised contract value increased 25% to US$145.2 million. Management EBITDA margin rose to 20%.1h ago
Seeking Alpha2h agoNVDA's data center revenue rises 110% Y/YData center revenue rose to $90 billion in FQ3'27 from $26.272 billion in FQ2'25. Hyperscale revenue reached $49 billion.2h ago
The Economic Times2h agoNvidia tops Wall Street estimates in Q3 as NVDA shares riseNvidia released its first earnings report without Jensen Huang at the helm. The company expects fourth-quarter revenue of $130 billion, plus or minus 3%. That forecast is above analysts' expectations.2h ago
Seeking Alpha2h agoNRx outlines $400M ketamine market growing 17% a year, targeting 2027 NRX100 approvalNRx reported $1.2 million in third-quarter patient revenue alongside a net loss of $2.2 million. The FDA approved the company's preservative-free ketamine in October.2h ago